NASDAQ:AUPH - Aurinia Pharmaceuticals Stock Price, Forecast & News

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its earnings results on Thursday, November, 14th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. The biotechnology company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.79% and a negative net margin of 19,483.96%. View Aurinia Pharmaceuticals' Earnings History.

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Aurinia Pharmaceuticals.

8 analysts have issued 1 year price targets for Aurinia Pharmaceuticals' stock. Their forecasts range from $11.00 to $32.00. On average, they anticipate Aurinia Pharmaceuticals' stock price to reach $22.29 in the next year. This suggests a possible upside of 20.1% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

News stories about AUPH stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 5,500,000 shares, a decline of 23.7% from the December 31st total of 7,210,000 shares. Based on an average trading volume of 3,460,000 shares, the short-interest ratio is presently 1.6 days. Currently, 6.9% of the company's shares are sold short. View Aurinia Pharmaceuticals' Current Options Chain.

Some companies that are related to Aurinia Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), The Medicines (MDCO), Horizon Therapeutics (HZNP), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR) and Allakos (ALLK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Array Biopharma (ARRY), Cara Therapeutics (CARA), Micron Technology (MU), Exelixis (EXEL), Corbus Pharmaceuticals (CRBP), Novavax (NVAX) and Synergy Pharmaceuticals (SGYP).

Aurinia Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SG Americas Securities LLC (0.00%), Patriot Financial Group Insurance Agency LLC (0.00%), Lindbrook Capital LLC (0.00%) and Steward Partners Investment Advisory LLC (0.00%).

AUPH stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC and Patriot Financial Group Insurance Agency LLC.

AUPH stock was bought by a variety of institutional investors in the last quarter, including Lindbrook Capital LLC and Steward Partners Investment Advisory LLC.

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AUPH stock can currently be purchased for approximately $18.56.

Aurinia Pharmaceuticals has a market capitalization of $2.07 billion and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]